comprehensive -WSS

comprehensive

author：focus 2025-10-01 17:34:36 - browse：3414

Microsoft's head of research Peter Lee speaking at STAT Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

SAN FRANCISCO — Surging interest in generative AI among medical professionals since ChatGPT’s launch is perhaps a testament to its potential — but it could also lead clinicians, and patients to experiment with it before there is wider consensus on how to navigate its biases and other pitfalls, Microsoft’s head of research Peter Lee said Thursday at STAT’s Breakthrough Summit.

About a month after OpenAI — Microsoft has a significant financial stake in the company — launched its chatbot in 2022 on November 30, which happened to be Lee’s birthday, he got a note from a doctor friend who said he’d used it so his receptionist could file after-visit summaries for patients. While Lee and a handful of other doctors at Microsoft had been impressed with the GPT-4’s capabilities, they knew it had weaknesses.

“The emotions were really mixed. I mean we were thrilled,” he said, but then “just within minutes there’s a feeling of dread. We had already come to the realization that GPT-4 would be prone to issues, issues of bias, hallucination, mathematical and logical errors,” he said. “And so, there’s an immediate question: ‘Should we allow this to happen?’”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： A revolution in caring for preterm infants

knowledge

WSS

Massive project maps cells in human brain in unprecedented detail

Female surgeons have lower rates of long

STAT Readout: Today's biotech news includes Sana and Amylyx

European regulators consider appeal over Amylyx ALS drug

What's changing in Medicare's open enrollment this year?

Peter Marks talks Operation Warp Speed for Rare Diseases

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

explore

ChatGPT in medicine: STAT answers readers' burning questions

Nick Jonas talks about managing diabetes along with his career

Walensky prepares to leave CDC — and Congress — behind

STAT Readout: Today's biotech news includes Sana and Amylyx

Sports medicine is finally prioritizing gender equality

Better Therapeutics data on benefit with GLP

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Information blocking fines are now fair game in health care

Apple is now the first public company to be valued at $3 trillion

White House Covid adviser calls on docs to combat misinformation

knowledge

Humana CEO Bruce Broussard to step down in 2024

European regulators consider appeal over Amylyx ALS drug

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

House panel takes first step toward fixing drug shortages

How doctors and nurses shape Google's AI

'A game

focus

knowledge

hotspot

explore